Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BCRXBullishCorporate Developmentsnews

High materiality8/10

BioCryst Reports Strong Q1 Results Amid Mixed Analyst Ratings

May 7, 2026, 2:06 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Despite a slight stock price decrease, positive earnings and guidance typically support price appreciation. Analysts encouraging outlooks bolster investor confidence, potentially stabilizing the stock.

AI summary

What happened, with direct paths to the underlying reporting

BioCryst Pharmaceuticals posted strong Q1 earnings and sales that beat analyst expectations, affirming FY2026 guidance. However, the stock saw a slight decline amid mixed analyst price target adjustments.

BCRX reported Q1 earnings of 14 cents, beating 5 cent estimate.
Sales reached $156.413 million, exceeding $151.123 million consensus.
Affirmed FY2026 sales guidance of $635 million-$660 million.
Wedbush analyst lowered price target from $22 to $21.
Citizens analyst raised price target from $25 to $28.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.